KRAS and neoplasm: In this respect, a spate of recent high profile reports has described a new generation of SMIs that trap mutant KRAS (G12C) in a GDP‐bound inactive state, with one compound in particular (ARS‐1620) displaying robust anti‐tumor activity in numerous NSCLC xenograft models harboring the KRASG12C allele (Patricelli et al, 2016; Janes et al, 2018).